Tesofensine
Triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine). Not a peptide. Phase II data shows ~6.7–11.3% body weight reduction. Oral small molecule with an ~8-day half-life that creates slow, cumulative pharmacological changes.
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, dopamine, and norepinephrine — distinct from GLP-1 class agents and all peptide compounds in this database. It was originally investigated for Alzheimer’s and Parkinson’s disease before metabolic effects were identified in clinical study participants.
Phase II clinical trials demonstrated dose-dependent weight loss: approximately 6.7% body weight reduction at 0.25 mg/day and 11.3% at 0.5 mg/day over 24 weeks. These outcomes compared favorably to obesity medications available at the time. However, cardiovascular effects including heart rate increases and blood pressure elevation at higher doses were identified and affected the risk/benefit assessment.
Tesofensine’s ~8-day half-life means dose changes produce slow cumulative changes rather than rapid adjustments — a key pharmacokinetic consideration affecting titration and side effect management. This is not a conventional peptide with a short action window; pharmacological changes accumulate slowly over time.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
Tesofensine is not FDA-approved for obesity. Cardiovascular effects — heart rate and blood pressure increases — are the primary safety concern at 0.5 mg/day. CNS effects including insomnia and dry mouth. Significant interaction potential with any monoamine-active medications. Oral small molecule; no reconstitution required. Research use only. All information for educational reference only.